This evidence indicated that the anti-cancer potential of HDAC inhibitors could be promoted in combination with PI3K inhibitors against tamoxifen-resistant breast cancer cells through the direction of the cancer cells to the S phase. Here, HDAC9 is linked to breast cancer.